Summary

This article is important in that it confirms another terbinafine competitor to the Novartis Lamisil brand is being released. The majority of terbinafine prescriptions in North America are generic. The market for this product will be good at least until more effective oral or topical agents are released. The majority of the prescriptions are for onychomycosis (toenail fungus). The newer products will be released in 3-4 years, at which time the market for terbinafine will shrink significantly.

Analysis

The companies most impacted will be Novartis which will lose market share for its Lamisil product. Aurobindo and other generic manufacturers will benefit from the release of this generic. This will occur until newer and more effective topical and oral antifungals for onychomycosis are released in the next 3-4 years.

Sunil Dhawan consults with leading institutions through GLG

Sunil Dhawan, Clinical Assistant Professor of Dermatology

What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Clinical Assistant Professor of Dermatology, STANFORD UNIVERSITY

 
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.